Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TAF1 | P21675 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.40 |
| ▸ | BRD8 | Q9H0E9 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17698720 | 0.92 | BRD4 (0.52) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL17867508 | 0.92 | BRD4 (0.52) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL17698686 | 0.91 | BRD4 (0.51) | BRD4CYP1A2ALDH1A1TRIM24TAF1 | |
| SCHEMBL17698758 | 0.91 | BRD4 (0.50) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL17867518 | 0.83 | BRD4 (0.65) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL17698770 | 0.82 | BRD4 (0.60) | BRD4CYP1A2ALDH1A1TRIM24TAF1 | |
| SCHEMBL17875706 | 0.81 | BRD4 (0.54) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL17698644 | 0.80 | BRD4 (0.60) | BRD4CYP1A2TRIM24TAF1BRD2 | |
| SCHEMBL17698750 | 0.79 | BRD4 (0.52) | BRD4TRIM24TAF1BRD2BRPF1 | |
| SCHEMBL17875713 | 0.78 | BRD4 (0.61) | BRD4TRIM24TAF1BRD2BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885CYP1A2 4461/4885ALDH1A1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.